Cell & Gene Therapy: Maximizing Commercialization Potential

How to Navigate the Less Obvious Barriers to Brining Advanced & Highly Targeted Treatments to Market

With so many exciting novel treatments emerging from the labs, particularly in the field of gene therapy, biotechs and pharma companies need to understand the potential unknowns as well as the known considerations if they are to optimize their impact in the real world.

In April 2023, in a second live Science Huddle debate, big names from the forefront of gene therapy, as well as regulatory and commercialization experts, came together to advise on some of the less obvious barriers to commercialization, and the most effective strategies to ensure a smooth and viable path to market.

Get your free copy

Get your free copy


We are now Cencora PharmaLex 

PharmaLex is now part of Cencora, a leading global healthcare company with a foundation in pharmaceutical distribution. In 2024 and beyond PharmaLex and all the companies in PharmaLex family will begin a journey to becoming Cencora as well. Cencora brings the companies and services together under one new name. The name will change, but the level of attention and service you receive remains the same.  

Know more